Viatris Got Notice That Applicant ANDA Seeking FDA Approval For Generic To Tyrvaya
Portfolio Pulse from Benzinga Newsdesk
Viatris (VTRS) received notice that an applicant has submitted an Abbreviated New Drug Application (ANDA) to the FDA, seeking approval for a generic version of Tyrvaya.
June 13, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viatris may face increased competition if the FDA approves a generic version of Tyrvaya, potentially impacting its revenues.
Viatris received notice of an ANDA submission for a generic version of Tyrvaya. If the FDA approves the generic drug, it could lead to increased competition for Viatris, potentially impacting its revenues and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100